Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal

Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.

PFEPositive Net Change ALKSPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot

AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.

AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab

Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.

PFEPositive Net Change VRTXPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

PFEPositive Net Change MRNAPositive Net Change COLLPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines

Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.

COLLPositive Net Change MTNBPositive Net Change BNTXPositive Net Change